SANION

Saniona

Market Cap 558.1M

Saniona is a drug research and development company based in Copenhagen. The company target diseases in the area of Central Nervous System (CNS), metabolic diseases, autoimmune diseases, and treatment of pain. The research platform is focused on ion channels which controls the passage of charged ions across cell membranes. The company was founded in 2011 and has 24 employees. Saniona has been listed since 2014, and is since 2017 listed on the main market of OMX Nasdaq Stockholm (List: Small Cap).

+ more

Redeye Research

Reports

Notes

Today
Day High
25.70
25.15
Day Low
25.10
Day Open
25.10
Prev Close
25.30
VWAP
25.2
Volume
7K
Turnover
0.172M
Top Broker
UBS
VWAP
25.5
Avg Volume
30K
Avg Turnover
0.765M
Top Brokers
AVA/UBS
VWAP
25.7
Avg Volume
24K
Avg Turnover
0.620M
Top Brokers
AVA/UBS
VWAP
26.1
Avg Volume
24K
Avg Turnover
0.629M
Top Brokers
AVA/NON
52 week summary
Price Range
24.8
Last
55.0
Beta
N/A
Market Cap
558.1M
Total Return
-44.5%
Trailing P/E
-9.8
Div Yield
0.0%
Shares Outstanding
22.1M
Next Earnings Date
24 May
Stock Exchange
NASDAQ Stockholm
5 day chart Go to advanced chart

Identify and measure trend strength in stocks with our Momentum tool to identify potential entry and exit signals. The tool provides a set of the most simple but powerful indicators that identify whether a stock is under sell or buy pressure.

Relative Price Strength
Change 3 Months -23.4%
Change 12 Months -41.5%
Volume Trend
Average Volume 10 vs 60 Days -13.5%
Price VS
52 Week High -54.3%
50 Day Moving Average -7.0%
200 Day moving Average -21.9%

Add article markers

Compare Saniona to

Prev Close 0 Change 0
High 0 Avg Daily Volume 0
Low 0 Avg Daily Turnover 0
  • Management
  • Jörgen Drejer, CEO
  • Thomas Feldthus, CFO
  • Executive board
  • J. Donald DeBethizy, Chairman of the board
  • Jørgen Drejer
  • Leif Andersson
  • Carl Johan Sundberg
Last updated: 2018-02-27 Source: Redeye
Major Owners Equity Votes
Jörgen Drejer 11.3%
11.3%
Thomas Feldthus 8.6%
8.6%
Avanza Pension 5.3%
5.3%
Leif Andersson Consulting ApS 4.6%
4.6%
Palle Christophersen 3.8%
3.8%
Claus Brästrup 3.4%
3.4%
Nordnet Pensionsförsäkring 2.7%
2.7%
Janus Schreiber Larsen 1.8%
1.8%
Nordea Liv & Pension 1.5%
1.5%
Christian Olofsson 1.3%
1.3%
Last updated: 2018-02-26 Source: Redeye/Holdings
  •  
  • Profitability
  • ROE
  • ROCE
  • ROIC
  • EBITDA margin
  • EBIT margin
  • Net margin
  • Per share data (SEK)
  • EPS
  • EPS adj
  • Dividend
  • Net debt
  • Total shares
  • Valuation
  • EV (SEKm)
  • P/E
  • P/E diluted
  • P/Sales
  • EV/Sales
  • EV/EBITDA
  • EV/EBIT
  • P/BV
  • Capital structure
  • Equity ratio
  • Debt/equity ratio
  • Net debt(SEKm)
  • Capital employed(SEKm)
  • Capital turnover rate
  • (SEKm)
  • Net sales
  • Total operating costs
  • EBITDA
  • Depreciation
  • Amortization
  • Impairment charges
  • EBIT
  • Share in profits
  • Net financial items
  • Exchange rate dif.
  • Pre-tax profit
  • Tax
  • Net earnings
  • (SEKm)
  • Assets
  • Current assets
  • Cash in banks
  • Receivables
  • Inventories
  • Other current assets
  • Current assets
  • Fixed assets
  • Tangible assets
  • Associated comp.
  • Investments
  • Goodwill
  • Cap. exp. for dev.
  • O intangible rights
  • O non-current assets
  • Total fixed assets
  • Deferred tax assets
  • Total (assets)
  • Liabilities
  • Current liabilities
  • Short-term debt
  • Accounts payable
  • O current liabilities
  • Current liabilities
  • Long-term debt
  • O long-term liabilities
  • Convertibles
  • Total Liabilities
  • Deferred tax liab
  • Provisions
  • Shareholders' equity
  • Minority interest (BS)
  • Minority & equity
  • Total liab & SE
  • (SEKm)
  • Net sales
  • Total operating costs
  • Depreciations total
  • EBIT
  • Taxes on EBIT
  • NOPLAT
  • Depreciation
  • Gross cash flow
  • Change in WC
  • Gross CAPEX
  • Free cash flow
  • 2015
  •  
  • 0.0%
  • -106.1%
  • 0.0%
  • -200.4%
  • -206.0%
  • -168.4%
  •  
  • 0.00
  • 0.00
  • 0.00
  •  
  • 0.0
  •  
  • -47.0
  • 0.0
  • 0.0
  • 0.0
  • -3.4
  • 1.7
  • 1.7
  • 0.0
  •  
  • 91.8%
  • 0.0%
  • -47
  • 6
  • 0.2
  • 2015
  •  
  •  
  • 47
  • 8
  • 0
  • 0
  • 55
  •  
  • 1
  • 0
  • 2
  • 0
  • 0
  • 0
  • 0
  • 2
  • 0
  • 58
  •  
  •  
  • 0
  • 5
  • 0
  • 5
  • 0
  • 0
  • 0
  • 5
  • 0
  • 0
  • 53
  • 0
  • 53
  • 58
  • 2015
  • 14
  • -41
  • -1
  • -28
  • 0
  • -28
  • 1
  • -27
  • -4
  • -3
  • -28
  • 2015 Q1
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2015 Q2
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2015 Q3
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2015 Q4
  • 14
  • -41
  • -27
  • -1
  • 0
  • 0
  • -28
  • 0
  • -1
  • 0
  • -29
  • 6
  • -23
  • 2016
  •  
  • 4.1%
  • 7.8%
  • 70.0%
  • 6.1%
  • 5.6%
  • 3.0%
  •  
  • 0.00
  • 0.00
  • 0.00
  •  
  • 0.0
  •  
  • -53.3
  • 0.0
  • 0.0
  • 0.0
  • -0.7
  • -11.7
  • -12.8
  • 0.0
  •  
  • 76.7%
  • 0.0%
  • -53
  • 1
  • 1.1
  • 2016
  •  
  •  
  • 53
  • 15
  • 0
  • 0
  • 68
  •  
  • 1
  • 0
  • 2
  • 0
  • 0
  • 0
  • 0
  • 3
  • 0
  • 71
  •  
  •  
  • 0
  • 17
  • 0
  • 17
  • 0
  • 0
  • 0
  • 17
  • 0
  • 0
  • 54
  • 0
  • 54
  • 71
  • 2016
  • 75
  • -70
  • 0
  • 4
  • 0
  • 4
  • 0
  • 5
  • 5
  • -1
  • 6
  • 2016 Q1
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2016 Q2
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2016 Q3
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2016 Q4
  • 75
  • -70
  • 5
  • 0
  • 0
  • 0
  • 4
  • 0
  • 1
  • 0
  • 5
  • -3
  • 2
  • 2017
  •  
  • -122.5%
  • -124.5%
  • -5,770.7%
  • -273.7%
  • -276.4%
  • -272.0%
  •  
  • -2.59
  • -2.59
  • 0.00
  •  
  • 21.8
  •  
  • -22.3
  • 0.0
  • 0.0
  • 0.0
  • -1.1
  • 0.4
  • 0.4
  • 0.0
  •  
  • 77.8%
  • 0.0%
  • -22
  • 15
  • 0.4
  • 2017
  •  
  •  
  • 22
  • 11
  • 0
  • 0
  • 33
  •  
  • 1
  • 0
  • 6
  • 0
  • 0
  • 0
  • 0
  • 8
  • 7
  • 48
  •  
  •  
  • 0
  • 11
  • 0
  • 11
  • 0
  • 0
  • 0
  • 11
  • 0
  • 0
  • 38
  • 0
  • 38
  • 48
  • 2017
  • 21
  • -77
  • -1
  • -57
  • 0
  • -57
  • 1
  • -57
  • -2
  • -6
  • -72
  • 2017 Q1
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2017 Q2
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2017 Q3
  • 16
  • -56
  • -40
  • 0
  • 0
  • 0
  • -41
  • 0
  • -1
  • 0
  • -42
  • 0
  • -42
  • 2017 Q4
  • 5
  • -21
  • -16
  • 0
  • 0
  • 0
  • -17
  • 0
  • 2
  • 0
  • -15
  • 0
  • -15
  • 2018 E
  • 2018 E
  • 2018 E
  • 2018 Q1 E
  • 2018 Q2 E
  • 2018 Q3 E
  • 2018 Q4 E
  • 2019 E
  • 2019 E
  • 2019 E
  • 2019 Q1 E
  • 2019 Q2 E
  • 2019 Q3 E
  • 2019 Q4 E
  • 2020 E
  • 2020 E
  • 2020 E
  • 2020 Q1 E

Estimated Values is behind membership

To access members-only content, you must login or register an account.

Our membership is about gaining access to unique research and knowledge through our analysts and a network of peers. Be the first to get information about news and research in the Nordic life science and technology sectors and use our tools and education to reach your personal and professional goals in investing.

Last updated: 2018-02-28 Source: Redeye
Source: Redeye

Presentations, research interviews and videos from our events listed here.

Source: Redeye

When selecting comparable companies, we try to group companies that are in the same or similar sector or subsector. But, more important, have growth, margins and risk characteristics similar to the company being valued.